Cargando…

A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease

BACKGROUND/AIMS: The aim of this study was to evaluate the efficacy and cost efficiency of omeprazole 10 mg and rabeprazole 10 mg once daily for 24 weeks in the maintenance therapy. METHODS: This was a randomized, open-label study enrolling 279 patients with erosive esophagitis A or B (Los Angeles c...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jung Ho, Park, Hyojin, Lee, Dong Ho, Sung, In Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Neurogastroenterology and Motility 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644658/
https://www.ncbi.nlm.nih.gov/pubmed/23667753
http://dx.doi.org/10.5056/jnm.2013.19.2.219
_version_ 1782268462738964480
author Park, Jung Ho
Park, Hyojin
Lee, Dong Ho
Sung, In Kyung
author_facet Park, Jung Ho
Park, Hyojin
Lee, Dong Ho
Sung, In Kyung
author_sort Park, Jung Ho
collection PubMed
description BACKGROUND/AIMS: The aim of this study was to evaluate the efficacy and cost efficiency of omeprazole 10 mg and rabeprazole 10 mg once daily for 24 weeks in the maintenance therapy. METHODS: This was a randomized, open-label study enrolling 279 patients with erosive esophagitis A or B (Los Angeles classification) and typical gastroesophageal reflux disease symptoms. Patients who showed complete endoscopic and symptomatic healing after 8 weeks of proton pump inhibitor treatment were randomly allocated to maintenance treatment with omeprazole 10 mg once daily or rabeprazole 10 mg once daily for 42 weeks. The primary efficacy endpoint was the proportion of patients with symptomatic remission at 42 weeks. RESULTS: At the end of 42 weeks of maintenance therapy, 96.4% of omeprazole and 95.1% of rabeprazole treated patients remained symptom free (P > 0.05). Two drugs were also comparable with regard to the severity and frequency of reflux symptoms during the maintenance phase (P > 0.05). By the cost-minimization analysis, the mean total costs per patient for remaining symptom-free for 6 months were 241,775 won for omeprazole and 287,115 won for rabeprazole, respectively. CONCLUSIONS: Omeprazole 10 mg appeared to have similar efficacy in maintaining symptomatic remission as rabeprazole 10 mg, but was superior to rabeprazole 10 mg in terms of cost efficiency in the maintenance therapy of gastroesophageal reflux disease symptoms.
format Online
Article
Text
id pubmed-3644658
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-36446582013-05-10 A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease Park, Jung Ho Park, Hyojin Lee, Dong Ho Sung, In Kyung J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: The aim of this study was to evaluate the efficacy and cost efficiency of omeprazole 10 mg and rabeprazole 10 mg once daily for 24 weeks in the maintenance therapy. METHODS: This was a randomized, open-label study enrolling 279 patients with erosive esophagitis A or B (Los Angeles classification) and typical gastroesophageal reflux disease symptoms. Patients who showed complete endoscopic and symptomatic healing after 8 weeks of proton pump inhibitor treatment were randomly allocated to maintenance treatment with omeprazole 10 mg once daily or rabeprazole 10 mg once daily for 42 weeks. The primary efficacy endpoint was the proportion of patients with symptomatic remission at 42 weeks. RESULTS: At the end of 42 weeks of maintenance therapy, 96.4% of omeprazole and 95.1% of rabeprazole treated patients remained symptom free (P > 0.05). Two drugs were also comparable with regard to the severity and frequency of reflux symptoms during the maintenance phase (P > 0.05). By the cost-minimization analysis, the mean total costs per patient for remaining symptom-free for 6 months were 241,775 won for omeprazole and 287,115 won for rabeprazole, respectively. CONCLUSIONS: Omeprazole 10 mg appeared to have similar efficacy in maintaining symptomatic remission as rabeprazole 10 mg, but was superior to rabeprazole 10 mg in terms of cost efficiency in the maintenance therapy of gastroesophageal reflux disease symptoms. Korean Society of Neurogastroenterology and Motility 2013-04 2013-04-16 /pmc/articles/PMC3644658/ /pubmed/23667753 http://dx.doi.org/10.5056/jnm.2013.19.2.219 Text en © 2013 The Korean Society of Neurogastroenterology and Motility http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Jung Ho
Park, Hyojin
Lee, Dong Ho
Sung, In Kyung
A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title_full A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title_fullStr A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title_full_unstemmed A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title_short A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease
title_sort randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644658/
https://www.ncbi.nlm.nih.gov/pubmed/23667753
http://dx.doi.org/10.5056/jnm.2013.19.2.219
work_keys_str_mv AT parkjungho arandomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT parkhyojin arandomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT leedongho arandomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT sunginkyung arandomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT parkjungho randomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT parkhyojin randomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT leedongho randomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease
AT sunginkyung randomizeddoubleblindedclinicaltrialtoassesstheefficacyandcosteffectivenessofomeprazolecomparedtorabeprazoleinthemaintenancetherapyofpatientswithgastroesophagealrefluxdisease